NEW YORK, NY--(Marketwire - September 24, 2012) -
Daxor Corporation (NYSE MKT: DXR
), an investment company with medical instrumentation and biotechnology operations, announced the presentation of a study entitled "Masked Polycythemia in Patients with Heart Failure and a Preserved Ejection Fraction: an underappreciated phenotype?" by Sahadeo D. Ramnauth, M.D., Sergio Teruya, M.D., Stephen Helmke, RDCS, and Matthew S. Maurer, M.D. at the Division of Cardiology, Columbia University Medical Center in New York. The study was presented at the recent Annual Heart Failure of Society of America convention in Seattle, Washington.
Polycythemia is a condition in which patients have an expanded red blood cell volume which can lead to an increase in strokes and heart attacks. Congestive heart failure patients usually have an expanded blood volume primarily from an expanded plasma volume. However, some patients also will have an expanded red cell volume as well. The usual treatment for heart failure patients is to administer diuretics which can cause a contraction of the blood volume but increase concentration of the red cells. An increase in red cell concentration has been shown in other studies to cause an increased incidence of thrombotic episodes such as heart attacks or strokes.
In this study group 17% of the patients were shown to have "hidden polycythemia" which would not be identified by routine blood tests. Such patients could be potentially harmed by excessive administration of diuretics to decrease their blood volume. Utilization of the blood volume analyzer which measures the patient's actual blood volume is the only accurate method to identify such patients and ensure appropriate treatment.
Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.